Group 1 - The company is shifting to a high-growth strategy by expanding sales capacity in key geographies with favorable market access and established distributor relationships [1] - Oncology performance remains stable, with CINVANTI showing resilience against competition while the planned wind-down of SUSTOL continues [1] Group 2 - Permanent J-Codes for ZYNRELEF and APONVIE have improved reimbursement clarity, facilitating broader adoption in hospitals and ambulatory surgery centers [2] - Operational improvements, including the CrossLink IGNITE distributor incentive program and the introduction of the vial access needle (VAN), have significantly reduced hospital workflow friction [2] Group 3 - Acute Care performance reached a strategic inflection point in Q4 2025, with ZYNRELEF and APONVIE achieving year-over-year revenue growth of 48% and 97%, respectively [3] - The company completed a financing round that eliminated a long-standing capital structure overhang, allowing management to focus on commercial execution [3] - Full year 2026 guidance projects net product sales between $173 million and $183 million, with adjusted EBITDA expected to remain positive between $10 million and $20 million [3] - The company plans to increase commercial investments starting mid-2026, which may temporarily moderate EBITDA growth to prioritize long-term revenue acceleration and free cash flow in 2027 [3] - ZYNRELEF's prefilled syringe presentation is undergoing 12 months of stability testing, with a targeted FDA approval and launch window in mid- to late 2027 [3] - APONVIE adoption is expected to accelerate in the second half of 2026 due to its inclusion in the Fifth Consensus Guidelines for PONV management [3] - The NOPAIN Act is anticipated to serve as a significant tailwind as provider awareness of separate reimbursement for non-opioid treatments increases throughout 2026 [3]

Core Insights - Heron Therapeutics reported revenue of $40.59 million for the quarter ended December 2025, reflecting a year-over-year decline of 0.5% and an EPS of -$0.02 compared to $0.02 a year ago, with the revenue aligning with Zacks Consensus Estimate of $0 million and an EPS surprise of +33.33% against a consensus estimate of -$0.03 [1] Financial Performance - The company’s net product sales for Acute Care from APONVIE reached $3.81 million, exceeding the two-analyst average estimate of $3.58 million, marking a year-over-year increase of +97.4% [4] - Oncology product sales from SUSTOL were reported at $1.33 million, below the two-analyst average estimate of $1.6 million, representing a year-over-year decline of -62.3% [4] - CINVANTI generated net product sales of $22.92 million, which was lower than the two-analyst average estimate of $24.15 million, indicating a year-over-year decrease of -14.7% [4] - ZYNRELEF's net product sales amounted to $12.53 million, surpassing the average estimate of $10.23 million from two analysts, with a year-over-year growth of +48.2% [4] Stock Performance - Over the past month, shares of Heron Therapeutics have declined by -18.8%, contrasting with the Zacks S&P 500 composite's increase of +0.6%, and the stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated approximately $155 million in total net revenues and delivered adjusted EBITDA of $14.7 million, exceeding the previously communicated guidance range of $9 million to $13 million [6][20] - Gross margin for the year was approximately 73%, reflecting continued improvements in cost discipline and product mix [6] Business Line Data and Key Metrics Changes - The acute care franchise increased more than 57% year-over-year in Q4 2025, with ZYNRELEF delivering 48% net revenue growth compared to Q4 2024, and APONVIE growing 97% over the same period [7][13] - Oncology franchise generated just over $105 million in net revenue for the full year 2025, representing a modest 7.8% decline compared to 2024, primarily due to the planned wind down of SUSTOL [10] Market Data and Key Metrics Changes - Acute care net sales were $16.3 million in Q4 2025, up from $12.3 million in Q3 2025, driven primarily by ZYNRELEF and APONVIE [13] - The company expects to see continued growth in unit volume for the CINV franchise, despite anticipated price erosion [25] Company Strategy and Development Direction - The strategy for 2026 and beyond includes accelerating the expansion of the commercial team in key markets, focusing on areas with strong success indicators and favorable reimbursement dynamics [8] - The company plans to increase commercial investments, which may temporarily moderate EBITDA growth, but are expected to drive meaningful growth in top-line revenue [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial inflection seen in Q4 2025 continuing into 2026, with a focus on maintaining EBITDA positivity while making targeted commercial investments [21] - The successful completion of financing has eliminated previous capital structure overhangs, providing the company with the financial flexibility needed for growth [21] Other Important Information - The company is advancing the prefilled syringe presentation for ZYNRELEF, with potential FDA approval anticipated in mid to late 2027 [9] - The inclusion of APONVIE in the newly released fifth consensus guidelines for the management of PONV is expected to support long-term utilization [7][16] Q&A Session Summary Question: Expectations for the CINV franchise and the NOPAIN Act's impact on ZYNRELEF - Management expects unit volume growth for the CINV franchise, with some price erosion, while the NOPAIN Act is anticipated to be a strong tailwind for ZYNRELEF [25][26] Question: Rollout status of the Vial Access Needle (VAN) and its impact on sales - The VAN rollout went smoothly, removing preparation challenges, and the company plans to continue leveraging this success for the prefilled syringe launch [30][32] Question: Update on the Slayback litigation regarding CINVANTI - The company is confident in its case and expects a decision from Judge Bryson before the 30-month stay [37] Question: Awareness efforts regarding the NOPAIN Act - The company is expanding its team to enhance awareness and understanding of the NOPAIN Act among providers, which is crucial for reimbursement [40] Question: Timeline for the impact of new consensus guidelines on PONV growth - The guidelines are expected to have a significant impact within 6 to 9 months as they are integrated into order sets and protocols [45][51]

Core Insights - Heron Therapeutics reported a 65% year-over-year net revenue growth in its Acute Care franchise, achieving $154.9 million in net revenue for 2025 and providing guidance for 2026 net revenue between $173 million and $183 million, with adjusted EBITDA expected to be between $10 million and $20 million [1][3]. Financial Performance - The Acute Care franchise experienced a revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025 compared to 2024, indicating strong commercial acceleration [4]. - Total net revenue for 2025 was $154.9 million, up from $144.3 million in 2024, reflecting a 7.4% increase [9]. - For Q4 2025, total net revenue was $40.6 million, slightly down from $40.8 million in Q4 2024, marking a 0.5% decrease [10]. Product Updates - ZYNRELEF, a key product, received a permanent product-specific J-Code (J0668) from CMS, effective October 1, 2025, which streamlines reimbursement processes [7]. - The transition to the Vial Access Needle for ZYNRELEF has been completed, enhancing product handling and sterility in hospitals and surgical centers [7]. - APONVIE, another significant product, was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its clinical importance [7]. Market Position and Strategy - The CEO emphasized that the company is entering 2026 with strong momentum, driven by strategic decisions that have unlocked the potential of its assets, particularly ZYNRELEF [2]. - The company is focused on expanding demand signals and improving reimbursement clarity, positioning itself for continued market share gains and revenue growth in 2026 and beyond [2]. Oncology Franchise - The Oncology franchise generated over $105 million in net revenue for 2025, despite facing complex market dynamics [8].

Core Insights - The company reported strong growth in Q4 2025, particularly in its Acute Care franchise, with notable contributions from ZYNRELEF and APONVIE [1] - Overall revenue for Q4 was approximately $40.5 million, with a total net revenue of about $154.9 million for FY25 [1] Financial Performance - Q4 net revenue: approximately $40.5 million for the three months ended December 31 [1] - ZYNRELEF net revenue: approximately $12.5 million for Q4 [1] - APONVIE net revenue: approximately $3.8 million for Q4 [1] - CINVANTI net revenue: approximately $22.9 million for Q4 [1] - SUSTOL net revenue: approximately $1.3 million for Q4 [1] - FY25 total net revenue: approximately $154.9 million [1] - ZYNRELEF experienced the largest quarter-over-quarter revenue increase within the portfolio in Q4 [1]

Core Insights - Heron Therapeutics, Inc. reported preliminary, unaudited net revenue for Q4 and full-year 2025, indicating growth driven by its Acute Care franchise products, ZYNRELEF and APONVIE [1][2] Financial Performance - The company achieved net revenue of approximately $40.5 million for Q4 2025, with ZYNRELEF contributing approximately $12.5 million, APONVIE approximately $3.8 million, CINVANTI approximately $22.9 million, and SUSTOL approximately $1.3 million [7] - For the full year 2025, net revenue reached approximately $154.9 million, with ZYNRELEF showing a quarter-over-quarter revenue increase of about 35% compared to Q3 2025 [7] Product Information - ZYNRELEF is the first extended-release dual-acting local anesthetic approved for postoperative pain management, demonstrating significant efficacy in reducing pain and opioid use post-surgery [3] - APONVIE is a neurokinin 1 receptor antagonist for the prevention of postoperative nausea and vomiting, approved by the FDA in September 2022 and commercially available since March 2023 [5] - CINVANTI is indicated for the prevention of chemotherapy-induced nausea and vomiting, utilizing an IV formulation of aprepitant [8] Company Overview - Heron Therapeutics focuses on developing and commercializing therapeutic innovations aimed at improving patient care, leveraging advanced science and patented technologies [11]

Core Insights - Heron Therapeutics is a biotechnology company focused on pain management and cancer treatments, with key products ZYNRELEF and APONVIE showing significant revenue growth due to strategic initiatives [1] Financial Performance - On November 4, 2025, Heron Therapeutics reported an EPS of -$0.10, missing the estimated EPS of -$0.01, marking a decline from the previous year's loss of $0.03 per share, resulting in a negative surprise of 150% [2] - The company's revenue for the quarter was $38.21 million, below the estimated $39.03 million, but represents a 16.5% increase compared to the same period last year; however, it fell short of the Zacks Consensus Estimate of $38.57 million, resulting in a revenue surprise of -0.91% [3] Valuation Metrics - The company has a P/E ratio of approximately -182.81 and a price-to-sales ratio of about 1.13, indicating negative earnings and that investors are paying $1.13 for every dollar of sales; the enterprise value to sales ratio is approximately 2.20 [4] - The debt-to-equity ratio is about -6.48, indicating a significant level of debt relative to equity [4] Future Outlook - Heron Therapeutics remains optimistic about its future, reaffirming its 2025 net revenue guidance of $153 million to $163 million, with an adjusted EBITDA projected between $9 million and $13 million, focusing on new initiatives launched in the third quarter that are positively impacting commercial performance [5]

Financial Data and Key Metrics Changes - Total net revenues for Q3 2025 were $38.2 million, with year-to-date revenues of $114.3 million, resulting in adjusted EBITDA of $1.5 million for the quarter and $9.5 million year to date [5][21] - Gross margin was 68.8%, down from 71.2% in Q3 2024, primarily due to a one-time write-off of Sustol polymer inventory [6][18] - Net loss for Q3 2025 was $17.5 million, compared to a net loss of $4.8 million in Q3 2024, largely due to an $11.3 million loss on debt extinguishment [20] Business Line Data and Key Metrics Changes - Acute care portfolio net sales were $12.3 million in Q3 2025, up from $10.7 million in Q2 2025, with ZYNRELEF net sales growing 49% year-over-year to $9.3 million [12][16] - APONVIE net sales increased 173% year-over-year to $3 million, reflecting strong growth before the dedicated sales team was fully active [12][14] - Oncology franchise net sales were $25.9 million in Q3 2025, with CINVANTI net sales approximately $24 million, up about 6% year-over-year [15][16] Market Data and Key Metrics Changes - ZYNRELEF's average daily units increased from 882 in Q3 2024 to 1,127 in Q3 2025, with ordering accounts rising from 705 to 833 [13] - APONVIE's average daily units grew from 418 to 998, with ordering accounts increasing from 299 to 405 [14] Company Strategy and Development Direction - The company has implemented initiatives such as the CrossLink Ignite program and the launch of the 200 mg Vial Access Needle to enhance distributor engagement and product adoption [7][10] - The introduction of a permanent product-specific J-code for ZYNRELEF is expected to streamline reimbursement and improve access [9][11] - The company plans to wind down the commercialization of Sustol over the next 12 months while evaluating potential product updates for a possible reintroduction in late 2027 [16][49] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for ZYNRELEF and APONVIE, indicating a positive trajectory for the business moving forward [10][16] - The company reaffirmed its guidance for net revenue of $153 million to $163 million and adjusted EBITDA of $9 million to $30 million for the year [21] Other Important Information - Cash and short-term investments as of September 30, 2025, were $55.5 million, bolstered by $13.1 million from recent debt and equity transactions [21] - The company is seeing momentum from the No Pain Act, with approximately 75% of ZYNRELEF indicated procedures having some form of coverage [47] Q&A Session Summary Question: October sales increase for ZYNRELEF - Management confirmed an approximate 17-18% month-over-month increase in early October sales for ZYNRELEF [24] Question: Adjusted gross profit margin - Management confirmed that the adjusted gross profit margin, excluding a one-time stocking charge, would be around 74.5% [25][26] Question: Future sales team expansion - Management indicated that they are pleased with the structural changes made and are considering adding to the sales teams based on success in specific regions [35][38] Question: Inventory stocking benefit for ZYNRELEF - Management stated that there was minimal inventory stocking benefit from the launch of the 200 mg Vial Access Needle [39] Question: Long-term outlook for Sustol and Synvonti - Management acknowledged competitive pressures on Sustol and indicated plans to wind down its commercialization while exploring potential updates for a future reintroduction [49] Question: Impact of the No Pain Act - Management noted that momentum is building for the No Pain Act, with commercial payers beginning to provide separate reimbursement [46][47]

Core Insights - Heron Therapeutics reported financial results for Q3 and the first nine months of 2025, showing significant revenue growth and reaffirming its financial guidance for the year [1][7][3]. Financial Performance - Q3 2025 net revenue reached $38.2 million, a 16.5% increase from $32.8 million in Q3 2024 [7][9]. - Year-to-date revenue for 2025 is $114.3 million, up 10.4% from $103.5 million in the same period of 2024 [10]. - The company reaffirmed its 2025 net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9 million to $13 million [3][7]. Product Performance - ZYNRELEF net revenue grew 49% in Q3 2025 compared to Q3 2024, driven by the launch of the Vial Access Needle and enhanced distributor incentives [7][8]. - APONVIE net revenue surged 173% in Q3 2025 compared to Q3 2024, supported by increased adoption and a dedicated sales team [7][8]. - The Acute Care franchise reported a revenue growth of 67.2% year-over-year in Q3 2025 [8][9]. Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $55.5 million [8]. Corporate Updates - The company launched several new initiatives in Q3 2025 that are positively impacting commercial execution and product demand [2]. - A permanent product-specific J-code for ZYNRELEF was granted, effective October 1, 2025, which is expected to streamline reimbursement processes [8]. Conference Call - Heron will host a conference call and live webcast on November 4, 2025, to discuss these results and updates [11].

Core Insights - Heron Therapeutics reported a 55.5% increase in Acute Care segment revenue, but faced a GAAP revenue shortfall compared to analyst expectations and continued declines in the Oncology segment [1][5][7] - Net revenue (GAAP) for Q2 2025 was $37.2 million, slightly below the consensus estimate of $38.075 million, with a year-over-year growth of 3.3% [1][2] - The company achieved a positive adjusted EBITDA of $1.8 million, indicating improved operational leverage [2][8] Financial Performance - GAAP loss per share was $(0.02), missing the expectation of $(0.01), while operating losses narrowed [1][2] - Acute Care revenue reached $10.7 million, up from $6.9 million in Q2 2024, reflecting a 55.5% year-over-year increase [2][5] - Oncology segment revenue declined by 9.0%, with SUSTOL experiencing a significant drop of 43.4% [2][7] Business Overview - Heron Therapeutics focuses on developing and commercializing therapeutics for acute care and oncology, including pain management and anti-nausea drugs [3] - The company is emphasizing growth in the Acute Care business, particularly through products like ZYNRELEF and APONVIE [4][10] Product Performance - ZYNRELEF saw a 40.4% year-over-year growth in GAAP net revenue, with unit demand increasing by 6.3% compared to Q1 2025 [5] - APONVIE's revenue grew by 141.6% year-over-year, with a 19% sequential increase in unit demand [6] - The Oncology segment's decline was attributed to ongoing weakness in SUSTOL and CINVANTI, with no new product drivers announced [7] Operational Developments - Gross margin was reported at 73.5%, with operating expenses decreasing by $3.0 million year-over-year to $29.0 million [8] - Total debt was reduced to $145 million, with maturities extended to at least 2030, providing greater flexibility for growth [8] - Cash and short-term investments decreased to $40.6 million, with a notable inventory increase of almost $20 million over six months [9] Future Outlook - The company reaffirmed its full-year 2025 net revenue target of $153.0 million to $163.0 million, requiring at least $77 million in the second half of 2025 [11] - Adjusted EBITDA guidance was raised to $9.0 million to $13.0 million for full-year 2025, reflecting improved operating performance [11] - Future growth in Acute Care revenue is expected to be driven by commercial team expansion and the rollout of permanent reimbursement codes for ZYNRELEF [11]